SC14D9C 1 ef20067380_sc14d9c.htm SC14D9C

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14D-9

Solicitation/Recommendation Statement

Under Section 14(d)(4) of the Securities Exchange Act of 1934

LISATA THERAPEUTICS, INC.

(Name of Subject Company)

LISATA THERAPEUTICS, INC.

(Name of Person Filing Statement)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

128058302

(CUSIP Number of Class of Securities)

David J. Mazzo, Ph.D.

President and Chief Executive Officer

Lisata Therapeutics, Inc.

110 Allen Road, Second Floor

Basking Ridge, NJ 07920

(908) 841-0100

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications

on Behalf of the Person Filing Statement)

With copies to:

Jeffrey P. Schultz, Esq.

Ivan Presant, Esq.

Mintz Levin Cohn Ferris Glovsky &

Popeo, P.C.

919 Third Avenue

New York, NY 10022

(212) 935-3000

☒	Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

The information set forth under Items 1.01, 7.01 and 9.01 of the Current Report on Form 8-K filed by Lisata Therapeutics, Inc. on March 9, 2026 (including all exhibits attached thereto and incorporated therein by reference) is incorporated herein by reference.

SEC Form SC14D9C filed by Lisata Therapeutics Inc.